Companion Diagnostics - CDx Summit

This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics.

Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner.

This year, for the first time, the companion diagnostic community will meet to analyse and tackle the latest and greatest opportunities in the CDx. In this Summit you will learn more about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.


Key Practical Learning Points of the Summit:

  • The latest trends of companion diagnostics (CDx) development
  • Partnering strategies to achieve successful commercialization of CDx
  • Manufacture CDx at the anticipated scale
  • Pharmaceutical and Diagnostics Companies Perspectives
  • CDx development and pre-launch commercialization costs
  • Finding the appropriate business models for CDx companies
  • The laboratory developed test (LDT) & In vitro diagnostic (IVD) Models
  • Introduction of a strategy that can improve the existing models

Who Should Attend:

CEOs, Companion Diagnostics Vice-Presidents, Directors, Chief Medical Officers from:

  • Companion Diagnostics
  • Global Diagnostic
  • Worldwide Regulatory Strategy
  • Companion Diagnostic Development
  • Biomarkers
  • Regulatory Affairs
  • Medical Sciences
  • Companion Diagnostic Development
  • Principal Scientist
  • Diagnostic & Experimental Pathology
  • Corporate Development & Ventures

From Industries Including: 

  • Pharmaceutical
  • Biotechnology
  • Research Institutes
  • CD entities
Media partners